Recombinant Anti-CD2 x Anti-TCR (Vβ8) Bispecific Antibody (scIgG) (SCIGG-048)

Recombinant Anti-CD2 x Anti-TCR (Vβ8) Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD2 and anti-TCR (Vβ8) IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can activate T cells. It is designed for the research of Tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD2 & TCR (Vβ8)

Type

Single chain IgGs

Species Reactivity

Mouse

Application

FuncS; Promising therapeutic agent

Related Disease

Tumors

Targets

Target 1

CD2

Gene ID

12481

UniProt ID

P06729

Alternative Names

CD2; CD2 molecule; T11; SRBC; LFA-2; T-cell surface antigen CD2; leukocyte function-associated antigen-2; LFA-3 receptor; rosette receptor; erythrocyte receptor; lymphocyte-function antigen-2; T-cell surface antigen T11/Leu-5; CD2 antigen (p50), sheep red blood cell receptor

Target 2

TCR (Vβ8)

Gene ID

100124664

Alternative Names

Trbv8; T cell receptor beta variable 8; TCR; T-cell receptor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD2 x Anti-TCR (Vβ8) Bispecific Antibody (scIgG) (SCIGG-048). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD2 x Anti-TCR (Vβ8) Bispecific Antibody (scIgG) (CAT#: SCIGG-048)

Specifications

Targets

Customer Reviews and Q&As